Physician profile
Seth A Permann
NPI 1508855974
$8,537.44
in general payments reported to CMS, 2019-2025
19 companies · $2,478 in 2025
The $2,478 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $837 · 2022: $973 · 2023: $1,349 · 2024: $2,900 · 2025: $2,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,331 · Consulting Fee: $1,863 · Education: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.43 |
| Consulting Fee | $1,862.50 |
| Education | $533.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,131.03 | 2021-2025 | |
| Janssen Biotech, INC. | $2,168.73 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $463.08 | 2021-2025 | Ilumya |
| Galderma Laboratories, L.P. | $372.48 | 2021-2025 | Nemluvio, Dysport |
| Ucb, INC. | $331.89 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $296.24 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $257.03 | 2021-2025 | |
| Leo Pharma INC. | $216.43 | 2022-2025 | Anzupgo, Adbry |
| E.R. Squibb & Sons, L.L.C. | $196.84 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $174.96 | 2022-2025 | Dupixent |
| Dermavant Sciences, INC. | $172.28 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $141.92 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $130.32 | 2021-2024 | Ebglyss, Olumiant, Taltz |
| Genzyme Corporation | $101.36 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $92.02 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $89.54 | 2022-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.72 | 2024 | Spevigo |
| Organon LLC | $82.95 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $34.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Permann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.